Cyclophilin befits in the group of protein that
shows peptidyl-prolyl cis-trans isomerase activity, found in all types of
cells. In humans, 16 cyclophilins have been identified till date. Cyclophilin
A, a member of cyclophilin group, mediate the action of immunosuppressive
drugs. A ternary complex is formed when cyclophilin A interact with another
cyclosporin A and inhibits calcineurin protein that regulates cytokine gene
transcription.
Cyclophilin A is involved in trafficking of proteins that
distributes action of asialoglycoprotein receptor between plasma membrane and
endosomal pool; promotes nuclear export; and translates neuronal nuclei to
induce cell death in various pathological conditions which includes amyotrophic
lateral sclerosis and cerebral hypoxia-ischemia. In addition, cyclophilin plays
important role in cell signalling. Cyclophilin D is located in mitochondria and
regulates the opening of mitochondrial permeability transition pore.
Cyclophilins are involved in pathophysiology of neurodegenerative diseases.
Request to Get the Sample Pages at:
Several
companies, such as Ensemble Therapeutics, Debiopharm Group, and ContraVir
Pharmaceuticals Inc., are actively involved in the development of cyclophilin
inhibitors therapeutics. For instance, Ensemble Therapeutics is in the process
of developing a drug candidate that acts as a cyclophilin antagonist for the
treatment of Parkinson’s disease, amyotrophic lateral sclerosis, and hepatitis
B. Debiopharm Group is developing Debio 025 cyclophilin inhibitor for the
treatment of muscular dystrophy. Moreover, ContraVir Pharmaceuticals Inc. is
also developing CRV431 as a cyclophilin antagonist for the treatment of
hepatitis B.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.